Oliver R T
Department of Medical Oncology, Royal London Hospital Medical College.
Cancer Surv. 1990;9(2):333-68.
Recent observations have suggested that a major factor in the development of germ cell tumours may be excessive mitogenic stimulus developed because of failure of feedback suppression of the normal pituitary drive due to atrophic damage to germinal epithelium. With this observation and the increasing recognition that there is a common in situ stage which precedes both seminoma and malignant teratoma/non-seminoma there has been a polarisation of views regarding the relationship between seminoma and malignant teratoma/non-seminoma, with some authors viewing these two entities as separate unrelated transformational events while others hypothesise that seminoma is an interim stage of clonal evolution associated with increased malignant potential towards malignant teratoma/non-seminoma. This chapter reviews the clinical evidence supporting the concept of clonal evolution which arises from the observation that the modal DNA content of seminoma (3.6N) is intermediate between that of in situ carcinoma (4.2N) and malignant teratoma/non-seminoma (2.8N). These observations, taken with the observation that the median age of patients with mixed tumours containing both seminoma and non-seminoma elements (30 years) is intermediate between the slower growing seminoma (35 years) and faster growing malignant teratoma/non-seminoma (25 years), as well as studies of spontaneous regression, tumours in AIDS patients chemo/radio sensitivity and post mortem histology, provide the most convincing evidence supporting clonal evolution. However, these observations cannot explain the fact that some patients have more than one focus of tumour (which can be of different histological type) in a single testis with normal tubules in between, even if they have in situ carcinoma. An extreme manifestation is seen in patients who are treated and cured from metastases arising from one testicle who then die from metastases from a completely different histological type arising from a second transformation event of a germ cell in the contralateral testis. The conclusion from these observations is that it is indeed possible for polyclonal development of tumours to occur, as is seen for bladder and bowel tumours, but they do not detract from the concept that seminoma is an intermediate event in the evolution from in situ carcinoma to malignant teratoma/non-seminoma.
最近的观察结果表明,生殖细胞肿瘤发生发展的一个主要因素可能是,由于生发上皮的萎缩性损伤导致正常垂体驱动的反馈抑制失败,从而产生了过度的有丝分裂刺激。基于这一观察结果,以及越来越多的人认识到精原细胞瘤和恶性畸胎瘤/非精原细胞瘤之前存在一个共同的原位阶段,关于精原细胞瘤与恶性畸胎瘤/非精原细胞瘤之间的关系出现了两种极端观点,一些作者认为这两种实体是独立的、不相关的转化事件,而另一些人则假设精原细胞瘤是克隆进化的一个中间阶段,其向恶性畸胎瘤/非精原细胞瘤发展的恶性潜能增加。本章回顾了支持克隆进化概念的临床证据,该证据源于以下观察结果:精原细胞瘤的模态DNA含量(3.6N)介于原位癌(4.2N)和恶性畸胎瘤/非精原细胞瘤(2.8N)之间。这些观察结果,再加上含有精原细胞瘤和非精原细胞瘤成分的混合肿瘤患者的中位年龄(30岁)介于生长较慢的精原细胞瘤(35岁)和生长较快的恶性畸胎瘤/非精原细胞瘤(25岁)之间这一观察结果,以及对自发消退、艾滋病患者肿瘤的化疗/放疗敏感性和尸检组织学的研究,提供了支持克隆进化的最有说服力的证据。然而,这些观察结果无法解释这样一个事实,即一些患者在单个睾丸中存在多个肿瘤病灶(可以是不同的组织学类型),其间小管正常,即使他们患有原位癌。在因一个睾丸转移瘤接受治疗并治愈,随后死于对侧睾丸生殖细胞第二次转化事件产生的完全不同组织学类型转移瘤的患者中可以看到一种极端表现。从这些观察结果得出的结论是,肿瘤确实有可能发生多克隆发展,就像膀胱和肠道肿瘤那样,但它们并不影响精原细胞瘤是原位癌向恶性畸胎瘤/非精原细胞瘤进化过程中的一个中间事件这一概念。